Search

Your search keyword '"Salvatore Federico"' showing total 2 results
Start Over Author "Salvatore Federico" Publication Type Magazines
2 results on '"Salvatore Federico"'

1. Proteomics and Phospho-Proteomics Reveal Predictive Signatures of Response and Mechanisms of Resistance to Midostaurin Plus Chemotherapy in FLT3 Mutant Positive Acute Myeloid Leukemia

Author

Veiga Nobre, Luis Miguel Veiga, Pedicona, Salvatore Federico, Dokal, Arran, Arruda, Andrea, Smith, Ryan, Greenhalgh, Calum, Patella, Francesca, Casado-Izquierdo, Pedro, Wrench, Bela, Theaker, Jane, Thompson, Andrew, Minden, Mark D., Gribben, John G., Britton, David James, and Cutillas, Pedro

Abstract

Background:Midostaurin is approved for FLT3 mutant-positive (FLT3+) acute myeloid leukemia (AML), however efficacy has also been observed in a subpopulation of FLT3 mutant-negative AML, suggesting that FLT3 mutation is not the only determinant conferring midostaurin sensitivity.

Published
2021
Full Text
View/download PDF

2. Proteomics and Phospho-Proteomics Reveal Predictive Signatures of Response and Mechanisms of Resistance to Midostaurin Plus Chemotherapy in FLT3 Mutant Positive Acute Myeloid Leukemia

Author

Veiga Nobre, Luis Miguel Veiga, Pedicona, Salvatore Federico, Dokal, Arran, Arruda, Andrea, Smith, Ryan, Greenhalgh, Calum, Patella, Francesca, Casado-Izquierdo, Pedro, Wrench, Bela, Theaker, Jane, Thompson, Andrew, Minden, Mark D., Gribben, John G., Britton, David James, and Cutillas, Pedro

Abstract

Veiga Nobre: Kinomica Ltd.: Current Employment. Minden: Astellas: Consultancy. Gribben: Janssen: Honoraria, Research Funding; AZ: Honoraria, Research Funding; Abbvie: Honoraria; BMS: Honoraria; Gilead/Kite: Honoraria; Morphosys: Honoraria; Novartis: Honoraria; Takeda: Honoraria; TG Therapeutics: Honoraria. Britton: Kinomica Ltd.: Current Employment, Current equity holder in publicly-traded company.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results